ClinicalTrials.gg
CompletedNCT01265784Updated Jan 6, 2022Results posted

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

A Phase 2 interventional study of TP-434 and Ertapenem in Complicated Intra-abdominal Infection, sponsored by Tetraphase Pharmaceuticals, Inc.. Completed at 38 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-06.

Sponsored by Tetraphase Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a Phase 2, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of two dose regimens of TP-434 compared with ertapenem in the treatment of adult community-acquired complicated intra-abdominal infections (cIAIs).

02

Conditions studied

  • Complicated Intra-abdominal Infection
03

In context

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

This study's enrollment of 143 is close to the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.

Browse Intraabdominal Infections studies →

Lead sponsor

Tetraphase Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Abdominal pain/discomfort with onset prior to hospitalization
  • Evidence of a systemic inflammatory response
  • Physical findings consistent with intra-abdominal infection (IAI)
  • Clinical diagnosis of community-acquired IAI requiring urgent surgical or percutaneous intervention and not expected to require antibacterial therapy for longer than 14 days
  • (BMI) of ≤ 30 kilograms per square meter (kg/m\^2)
  • Able to provide . If the participant is unable to provide informed consent, the participant's legally acceptable representative may provide written consent in accordance with institutional guidelines
  • If female, not pregnant or nursing or, if of either: will commit to use at least two medically accepted, effective methods of (for example, condom, oral contraceptive, indwelling intrauterine device, hormonal implant/patch, injections, approved cervical ring) during study drug dosing and for 90 days following last study drug dose or practicing sexual abstinence

Exclusion criteria

Exclusion Criteria:

  • Symptoms related to diagnosis of complicated appendicitis (if current diagnosis) for \< 24 hours prior to current hospitalization
  • Previously hospitalized or admitted to a healthcare facility within the last 6 months
  • Managed by Staged Abdominal Repair or other open abdomen technique
  • Known at study entry to have an IAI caused by a pathogen(s) resistant to both study drug antibiotics
  • Acute Physiology and Chronic Health Evaluation (APACHE) II score > 25
  • Unlikely to survive the 6-8 week study period
  • Any rapidly-progressing disease or immediately life-threatening illness, including acute hepatic failure, respiratory failure and septic shock
  • Requirement for vasopressors at therapeutic dosages
  • Renal failure
  • Presence or possible signs of hepatic disease
  • Hematocrit \< 25% or \< 8 grams per deciliter (g/dL)
  • Neutropenia with \< 1000 cells per cubic millimeter (mm\^3)
  • count \< 50,000/mm3
  • Abnormal coagulation tests or participant on anticoagulants
  • condition, including known (HIV) positivity or acquired immune deficiency syndrome (AIDS), organ (bone marrow) transplant recipients, and hematological . Immunosuppressive therapy, including use of high-dose (for example, > 40 milligrams [mg] prednisone or equivalent per day for greater than 2 weeks)
  • History of reactions to tetracyclines or carbapenems
  • Participation in any drug or device study within 30 days prior to study entry
  • Known or suspected central nervous system (CNS) disorder that may predispose to seizures or lower seizure threshold
  • Previously received TP-434 in a clinical trial
  • More than 24 hours duration of systemic antibiotic coverage for current condition
  • Received ertapenem or any other carbapenem, or tigecycline for the current infection
  • Need for concomitant systemic antimicrobial agents other than study drug or received systemic (IV or oral) antibiotics in the last 3 months
  • Refusal of mechanical ventilation, dialysis or hemofiltration, cardioversion or any other resuscitative measures and drug/fluid therapy at time of consent
  • Known or suspected inflammatory bowel disease or associated visceral abscess
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    TP-434, 1.5 mg/kg q24h

    TP-434 was administered intravenously (IV) at a dose of 1.5 milligrams per kilogram of body weight (mg/kg) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.

    Drug: TP-434 · Drug: Placebo

  • Experimental
    TP-434, 1.0 mg/kg q12h

    TP-434 was administered IV at a dose of 1.0 mg/kg every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.

    Drug: TP-434 · Drug: Placebo

  • Active comparator
    Ertapenem, 1 g q24h

    Ertapenem was administered IV at a dose of 1 gram (g) q24h for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.

    Drug: Ertapenem · Drug: Placebo

Interventions

  • DrugTP-434

    Also known as: Eravacycline

  • Also known as: Invanz

  • DrugPlacebo

    Administered IV to maintain the blind.

06

What researchers measure

Primary outcomes

  1. Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Test-of-Cure Visit

    Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (Test-of-Cure \[TOC\] assessment was not available, death unrelated to cIAI, or some other reason).

    Time frame: TOC Visit (10-14 days after last dose of study drug)

Secondary outcomes

  1. Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at the End-of-Treatment (EOT) Visit

    Time frame: EOT Visit (4-14 days after first dose of study drug)

  2. Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at TOC Visit

    Time frame: TOC Visit (10-14 days after last dose of study drug)

  3. Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at the Follow-up Visit

    Time frame: Follow-up Visit (28-42 days after last dose of study drug)

  4. Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the EOT Visit

    Time frame: EOT Visit (4-14 days after first dose of study drug)

  5. Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the TOC Visit

    Time frame: TOC Visit (10-14 days after last dose of study drug)

  6. Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the Follow-up Visit

    Time frame: Follow-up Visit (28-42 days after last dose of study drug)

  7. Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the EOT Visit

    Time frame: EOT Visit (4-14 days after first dose of study drug)

  8. Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the TOC Visit

    Time frame: TOC Visit (10-14 days after last dose of study drug)

  9. Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the Follow-up Visit

    Time frame: Follow-Up Visit (28-42 days after last dose of study drug)

  10. Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the EOT Visit

    Time frame: EOT Visit (4-14 days after first dose of study drug)

  11. Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the TOC Visit

    Time frame: TOC Visit (10-14 days after last dose of study drug)

  12. Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the Follow-up Visit

    Time frame: Follow-up Visit (28-42 days after last dose of study drug)

  13. Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the EOT Visit

    Time frame: EOT Visit (4-14 days after first dose of study drug)

  14. Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Follow-up Visit

    Time frame: Follow-up Visit (28-42 days after last dose of study drug)

  15. Microbiologic Response to TP-434 and Ertapenem in the m-MITT Population at the EOT Visit

    Microbiological response was classified as favorable (eradication or presumed eradication), unfavorable (persistence, presumed persistence, superinfection, or new infection), or indeterminate (assessment not possible).

    Time frame: EOT Visit (4-14 days after first dose of study drug)

  16. Microbiologic Response to TP-434 and Ertapenem in the m-MITT Population at the TOC Visit

    Time frame: TOC Visit (10-14 days after last dose of study drug)

  17. Microbiologic Response to TP-434 and Ertapenem in the ME Population at the EOT Visit

    Time frame: EOT Visit (4-14 days after first dose of study drug)

  18. Microbiologic Response to TP-434 and Ertapenem in the ME Population at the TOC Visit

    Time frame: TOC Visit (10-14 days after last dose of study drug)

  19. Pharmacokinetics: Maximum Concentration (Cmax) of TP-434

    Time frame: Prior to first infusion and 1, 3, 7, 12, 48, and 108 hours after start of first infusion

  20. Pharmacokinetics: Area Under the Concentration Time Curve From Time 0 to 12 Hours (AUC[0-12]) of TP-434

    Time frame: Prior to first infusion and 1, 3, 7, 12, 48, and 108 hours after start of first infusion

07

Results

Posted Sep 4, 2015

Participant flow

Participant flow — Overall Study
MilestoneTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem, 1 g q24h
Started565730
Received at least 1 dose of study drug545629
Completed444926
Not completed1284
Withdrew: Lost to follow-up532
Withdrew: Withdrawal by subject050
Withdrew: Physician decision101
Withdrew: Adverse event100
Withdrew: Death300
Withdrew: Protocol violation200
Withdrew: Incorrectly randomized001

Outcome measures

PrimaryClinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Test-of-Cure Visit

Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (Test-of-Cure \[TOC\] assessment was not available, death unrelated to cIAI, or some other reason).

Time frame:
TOC Visit (10-14 days after last dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Test-of-Cure Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure394124
Failure302
Indeterminate000
SecondaryClinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at the End-of-Treatment (EOT) Visit
Time frame:
EOT Visit (4-14 days after first dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at the End-of-Treatment (EOT) Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure495228
Failure211
Indeterminate330
SecondaryClinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at TOC Visit
Time frame:
TOC Visit (10-14 days after last dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at TOC Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure464726
Failure312
Indeterminate581
SecondaryClinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at the Follow-up Visit
Time frame:
Follow-up Visit (28-42 days after last dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at the Follow-up Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure414524
Failure412
Indeterminate9103
SecondaryClinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the EOT Visit
Time frame:
EOT Visit (4-14 days after first dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the EOT Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure495228
Failure211
Indeterminate330
SecondaryClinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the TOC Visit
Time frame:
TOC Visit (10-14 days after last dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the TOC Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure464726
Failure312
Indeterminate581
SecondaryClinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the Follow-up Visit
Time frame:
Follow-up Visit (28-42 days after last dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the Follow-up Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure414524
Failure412
Indeterminate9103
SecondaryClinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the EOT Visit
Time frame:
EOT Visit (4-14 days after first dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the EOT Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure414426
Failure201
Indeterminate230
SecondaryClinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the TOC Visit
Time frame:
TOC Visit (10-14 days after last dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the TOC Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure394124
Failure302
Indeterminate361
SecondaryClinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the Follow-up Visit
Time frame:
Follow-Up Visit (28-42 days after last dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the Follow-up Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure363922
Failure402
Indeterminate583
SecondaryClinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the EOT Visit
Time frame:
EOT Visit (4-14 days after first dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the EOT Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure474727
Failure211
Indeterminate000
SecondaryClinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the TOC Visit
Time frame:
TOC Visit (10-14 days after last dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the TOC Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure464726
Failure312
Indeterminate000
SecondaryClinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the Follow-up Visit
Time frame:
Follow-up Visit (28-42 days after last dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the Follow-up Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure414523
Failure412
Indeterminate423
SecondaryClinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the EOT Visit
Time frame:
EOT Visit (4-14 days after first dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the EOT Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure404125
Failure201
Indeterminate000
SecondaryClinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Follow-up Visit
Time frame:
Follow-up Visit (28-42 days after last dose of study drug)
Reported as:
Number · participants
Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Follow-up Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Cure363921
Failure402
Indeterminate223
SecondaryMicrobiologic Response to TP-434 and Ertapenem in the m-MITT Population at the EOT Visit

Microbiological response was classified as favorable (eradication or presumed eradication), unfavorable (persistence, presumed persistence, superinfection, or new infection), or indeterminate (assessment not possible).

Time frame:
EOT Visit (4-14 days after first dose of study drug)
Reported as:
Number · participants
Microbiologic Response to TP-434 and Ertapenem in the m-MITT Population at the EOT Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Favorable414426
Unfavorable201
Indeterminate230
SecondaryMicrobiologic Response to TP-434 and Ertapenem in the m-MITT Population at the TOC Visit
Time frame:
TOC Visit (10-14 days after last dose of study drug)
Reported as:
Number · participants
Microbiologic Response to TP-434 and Ertapenem in the m-MITT Population at the TOC Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Favorable394224
Unfavorable302
Indeterminate351
SecondaryMicrobiologic Response to TP-434 and Ertapenem in the ME Population at the EOT Visit
Time frame:
EOT Visit (4-14 days after first dose of study drug)
Reported as:
Number · participants
Microbiologic Response to TP-434 and Ertapenem in the ME Population at the EOT Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Favorable404125
Unfavorable201
Indeterminate000
SecondaryMicrobiologic Response to TP-434 and Ertapenem in the ME Population at the TOC Visit
Time frame:
TOC Visit (10-14 days after last dose of study drug)
Reported as:
Number · participants
Microbiologic Response to TP-434 and Ertapenem in the ME Population at the TOC Visit
participantsTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Favorable394124
Unfavorable302
Indeterminate000
SecondaryPharmacokinetics: Maximum Concentration (Cmax) of TP-434
Time frame:
Prior to first infusion and 1, 3, 7, 12, 48, and 108 hours after start of first infusion
Reported as:
Mean · nanograms per milliliter (ng/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of TP-434
nanograms per milliliter (ng/mL)TP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12h
Pharmacokinetics: Maximum Concentration (Cmax) of TP-4341445.625 ± 1168.029952.608 ± 759.754
SecondaryPharmacokinetics: Area Under the Concentration Time Curve From Time 0 to 12 Hours (AUC[0-12]) of TP-434
Time frame:
Prior to first infusion and 1, 3, 7, 12, 48, and 108 hours after start of first infusion
Reported as:
Mean · nanogram*hours per milliliter (ng*h/mL)
Pharmacokinetics: Area Under the Concentration Time Curve From Time 0 to 12 Hours (AUC[0-12]) of TP-434
nanogram*hours per milliliter (ng*h/mL)TP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12h
Pharmacokinetics: Area Under the Concentration Time Curve From Time 0 to 12 Hours (AUC[0-12]) of TP-4344349.900 ± 2186.7913240.724 ± 1732.172

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TP-434, 1.5 mg/kg q24h—6/53 (11.3%)11/53 (20.8%)
TP-434, 1.0 mg/kg q12h—1/56 (1.8%)10/56 (17.9%)
Ertapenem 1 g q24h—1/30 (3.3%)7/30 (23.3%)
Most frequent serious events
Most frequent serious events
EventTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
Subdiaphragmatic AbscessInfections and infestations0/530/561/30
Lobar PneumoniaInfections and infestations1/530/560/30
Duodenal Ulcer HaemorrhageGastrointestinal disorders1/530/560/30
Abdominal Wall AbscessInfections and infestations1/530/560/30
Atrial FibrillationCardiac disorders1/530/560/30
EmbolismVascular disorders1/530/560/30
IleusGastrointestinal disorders1/530/560/30
Wound InfectionInfections and infestations0/531/560/30
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24h
NauseaGastrointestinal disorders1/536/562/30
Lipase IncreasedInvestigations3/534/562/30
VomitingGastrointestinal disorders3/531/560/30
Blood Amylase IncreasedInvestigations3/532/561/30
Abdominal PainGastrointestinal disorders2/530/560/30
ThrombophlebitisVascular disorders1/532/560/30
Application Site HypersensitivityGeneral disorders0/530/561/30
PyrexiaGeneral disorders1/531/561/30
HypersensitivityImmune system disorders0/530/561/30
HypoalbuminaemiaMetabolism and nutrition disorders1/530/561/30

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)TP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24hTotal
Mean43.6 ± 18.3942.1 ± 17.1641.8 ± 17.6042.6 ± 17.64
Sex: Female, Male
Sex: Female, Male(Participants)TP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24hTotal
Female1814840
Male384322103
Region of Enrollment
Region of Enrollment(participants)TP-434, 1.5 mg/kg q24hTP-434, 1.0 mg/kg q12hErtapenem 1 g q24hTotal
United States0011
Romania69621
Lithuania1713737
Bulgaria96318
Latvia89421
India1620945
08

Study locations

38 sites
  • Long Beach VA Medical Center
    Long Beach, California 90822, United States
  • Denver Health Medical Center
    Denver, Colorado 80204, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Barnes Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Mercury Street Medical Group
    Butte, Montana 59701, United States
  • MHAT "Yulia Vrevska - Byala" EOOD, Byala
    Byala, 7100, Bulgaria
  • UMHAT "Dr. Georgi Stranski" EAD, Pleven
    Pleven, 5800, Bulgaria
  • UMHAT "Sveti Georgi" EAD, Plovdiv
    Plovdiv, 4000, Bulgaria
  • MHAT "Russe" AD, Russe
    Russe, 7002, Bulgaria
  • MHAT "Tokuda Hospital Sofia" AD, Sofia
    Sofia, 1407, Bulgaria
  • UMHAT "Tzaritza Yoanna" EAD, Sofia
    Sofia, 1527, Bulgaria
  • UMHATEM "N.I. Pirogov" EAD, Sofia
    Sofia, 1606, Bulgaria
  • UMHATEM "N.I.Pirogov" EAD, Sofia
    Sofia, 1606, Bulgaria
  • Bangalore Medical College and Research Institute, Victoria Hospital
    Fort, Bangalore 560002, India
  • Amrita Institute of Medical Sciences and Research Centre
    Kochi, Kerala 682041, India
  • Sahyadri Munot Hospital
    Pune, Maharashtra 411042, India
  • S.R. Kalla Memorial Gastro & General Hospital
    Jaipur, Rajasthan, India
  • HCG-Medisurge Hospitals Pvt. Ltd.
    Ahmedabad, 380006, India
  • Santosh Hospital
    Bangalore, 560005, India
  • K.R. Hospital
    Bangalore, 560050, India
  • M.S. Ramalah Medical College and Hospitals
    Bangalore, 560054, India
  • Sai Vani Hospitals, Ltd.
    Hyderabad, 500029, India
  • Daugavpils Regional Hospital
    Daugavpils, LV-5417, Latvia
  • Jekabpils Regional Hospital
    Jekabpils, LV 5201, Latvia
  • Rezeknes Hospital
    Rezekne, LV-4601, Latvia
  • Vidzeme Hospital
    Valmiera, LV-4201, Latvia
  • Kaunas Hospital
    Kaunas, LT-45130, Lithuania
  • Kaunas Clinical Hospital
    Kaunas, LT-47144, Lithuania
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
    Kaunas, LT-50009, Lithuania
  • Klaipeda University Hospital
    Klaipeda, LT-92288, Lithuania
  • Vilnius University Hospital Santariskiu Clinics
    Vilnius, LT-08661, Lithuania
  • Vilnius City Clinical Hospital
    Vilnius, LT-10207, Lithuania
  • Emergency Clinical City Hospital
    Timisoara, Timis 300079, Romania
  • "Dr. Carol Davila" Clinical Nephrology Hospital General Surgery Clinic
    Bucharest, 010701, Romania
  • Emergency Clinical Hospital Bucharest
    Bucharest, 014461, Romania
  • Coltea Clinical Hospital
    Bucharest, 030171, Romania
  • :Sfantul loan" Clinical Emergency Hospital
    Bucharest, 042122, Romania
  • University Emergency Hospital Bucharest
    Bucharest, 050098, Romania
09

References and documents

Publications

  • Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, Walpole SM, Horn PT. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58(4):1847-54. doi: 10.1128/AAC.01614-13. Epub 2013 Dec 16. PubMed 24342651 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2010
First posted
Dec 23, 2010
Start
Jan 2011
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Sep 4, 2015
Last update
Jan 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01265784
Lead sponsor
Tetraphase Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Dec 23, 2010
Start date
Jan 2011
Primary completion
May 2012
Completion
May 2012
Results posted
Sep 4, 2015
Last update
Jan 6, 2022

Study contacts

Patrick T Horn, MD, PhD
study director · Tetraphase Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eravacycline

Start the discussion